Canagliflozin Combined with Metformin Versus Metformin Monotherapy for Endocrine and Metabolic Profiles in Overweight and Obese Women with Polycystic Ovary Syndrome: A Single-center, Open-labeled Prospective Randomized Controlled Trial

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2022 Sep 23

PMID 36147577

Authors

Jiaqi Zhang

Chuan Xing

Xiangyi Cheng

Bing He

Affiliations

Soon will be listed here.

Abstract

Objectives: Canagliflozin (CANA), a kind of sodium-glucose cotransporter-2 (SGLT-2) inhibition, study in which the role of CANA monotherapy in polycystic ovary syndrome (PCOS) has been investigated, and it could become a novel option in the PCOS treatment. Nevertheless, trials focused on SGLT-2 combination therapy's efficacy, and safety in PCOS patients are limited. This randomized controlled trial compared the efficacy and safety of CANA and metformin (MET) combination therapy and MET monotherapy in endocrine and metabolic profiles of overweight and obese women with polycystic ovary syndrome (PCOS).

Methods: Fifty-one overweight or obese non-diabetic PCOS women between 18 and 40 years old were enrolled. Patients were randomly allocated to receive either CANA/MET or MET treatment. The CANA/MET group received CANA 100 mg once daily plus MET 1000 mg twice daily, while the MET group received MET 1000 mg twice daily for three months. Changes in menstrual pattern, anthropometric parameters, gonadal parameters, glucose and lipid homeostasis, and adverse events (AEs) were evaluated.

Results: Compared with the MET group, women have a significantly lower level of total testosterone (TT), area under the curve for glucose (AUCGlu), and area under the curve for insulin (AUCIns) to AUCGlu ratio in the combination group. There were no significant differences in menstrual frequency, body weight, body mass index, follicle-stimulating hormone, luteinizing hormone, free androgen index, sex hormone-binding globulin, androstenedione, fasting blood glucose, fasting insulin, AUCIns, homeostasis model assessment-insulin resistance (HOMA-IR), triglycerides, total cholesterol, low-density lipoprotein cholesterol, apolipoprotein A1 (Apo A1), apolipoprotein B (Apo B), and APO B/A1 ratio. AEs were seen in 57.70% (15/26) and 68.00% (17/25) of patients in the CANA/MET and MET groups, respectively.

Conclusions: In overweight and obese women with PCOS, CANA and MET combination therapy may be similar to MET monotherapy in improving menstrual frequency, weight control, hyperandrogenemia, and relieving insulin resistance. CANA/MET may have more benefits in reducing TT, AUCGlu, and the AUCIns/AUCGlu ratio within three months than MET monotherapy.

Trial Registration: ClinicalTrials.gov, NCT04973891.

Citing Articles

Impact of dapagliflozin on metabolic phenotype, hormone levels, and fertility in female mice after prolonged high-fat diet.

Chen X, Xiao Z, Dai N, Fan M Front Endocrinol (Lausanne). 2025; 15:1457268.

PMID: 39906039 PMC: 11791800. DOI: 10.3389/fendo.2024.1457268.

Effects of SGLT-2 inhibitors on clinical and biological hyperandrogenism and menstruation irregularities in patients with polycystic ovary syndrome: A systematic review of randomized trials.

Mrabet H, Ben Salem H, Ach T, Ben Abdelkarim A, Alaya W SAGE Open Med. 2024; 12:20503121241308997.

PMID: 39713268 PMC: 11660270. DOI: 10.1177/20503121241308997.

Canagliflozin treatment prevents follicular exhaustion and attenuates hallmarks of ovarian aging in genetically heterogenous mice.

Isola J, Biswas S, Jayarathne H, Hubbart C, Hense J, Matsuzaki S Geroscience. 2024; .

PMID: 39672978 DOI: 10.1007/s11357-024-01465-w.

Correlation analysis of BMI with ovulation effect and clinical pregnancy rate in patients with polycystic ovary syndrome.

Zeng X, Yang C Am J Transl Res. 2024; 16(8):4174-4181.

PMID: 39262693 PMC: 11384404. DOI: 10.62347/KYES1276.

View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences.

Froldi G Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675438 PMC: 11054066. DOI: 10.3390/ph17040478.

References

Sanchez-Garrido M, Tena-Sempere M . Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020; 35:100937. PMC: 7115104. DOI: 10.1016/j.molmet.2020.01.001. View

Cowie M, Fisher M . SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020; 17(12):761-772. DOI: 10.1038/s41569-020-0406-8. View

Palomba S, Piltonen T, Giudice L . Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2020; 27(3):584-618. DOI: 10.1093/humupd/dmaa051. View

Wong J, Chan K, Lo K . Sodium-glucose co-transporter 2 inhibitors on weight change and cardiometabolic profiles in individuals with overweight or obesity and without diabetes: A meta-analysis. Obes Rev. 2021; 22(12):e13336. DOI: 10.1111/obr.13336. View

Caldwell A, Edwards M, Desai R, Jimenez M, Gilchrist R, Handelsman D . Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome. Proc Natl Acad Sci U S A. 2017; 114(16):E3334-E3343. PMC: 5402450. DOI: 10.1073/pnas.1616467114. View

Geffner M, Kaplan S, Bersch N, Golde D, Landaw E, Chang R . Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril. 1986; 45(3):327-33. View

Sadeghi H, Adeli I, Calina D, Docea A, Mousavi T, Daniali M . Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Repurposing. Int J Mol Sci. 2022; 23(2). PMC: 8775814. DOI: 10.3390/ijms23020583. View

Cai M, Shao X, Xing F, Zhang Y, Gao X, Zeng Q . Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial. Diabetes Obes Metab. 2021; 24(2):312-320. DOI: 10.1111/dom.14583. View

Maruthur N, Tseng E, Hutfless S, Wilson L, Suarez-Cuervo C, Berger Z . Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016; 164(11):740-51. DOI: 10.7326/M15-2650. View

10.

Elkind-Hirsch K, Chappell N, Seidemann E, Storment J, Bellanger D . Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021; 106(10):3019-3033. DOI: 10.1210/clinem/dgab408. View

11.

Kuchenbecker W, Groen H, van Asselt S, Bolster J, Zwerver J, Slart R . In women with polycystic ovary syndrome and obesity, loss of intra-abdominal fat is associated with resumption of ovulation. Hum Reprod. 2011; 26(9):2505-12. DOI: 10.1093/humrep/der229. View

12.

Clark A, Thornley B, Tomlinson L, Galletley C, Norman R . Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod. 1998; 13(6):1502-5. DOI: 10.1093/humrep/13.6.1502. View

13.

Baillargeon J, Nestler J . Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin?. J Clin Endocrinol Metab. 2005; 91(1):22-4. PMC: 3846532. DOI: 10.1210/jc.2005-1804. View

14.

Tan S, Ignatenko S, Wagner F, Dokras A, Seufert J, Zwanziger D . Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial. Diabetes Obes Metab. 2021; 23(11):2595-2599. DOI: 10.1111/dom.14495. View

15.

Moran L, Norman R, Teede H . Metabolic risk in PCOS: phenotype and adiposity impact. Trends Endocrinol Metab. 2015; 26(3):136-43. DOI: 10.1016/j.tem.2014.12.003. View

16.

Hollander P, Bays H, Rosenstock J, Frustaci M, Fung A, Vercruysse F . Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. Diabetes Care. 2017; 40(5):632-639. DOI: 10.2337/dc16-2427. View

17.

Glueck C, Goldenberg N . Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism. 2018; 92:108-120. DOI: 10.1016/j.metabol.2018.11.002. View

18.

Bays H, Weinstein R, Law G, Canovatchel W . Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring). 2013; 22(4):1042-9. PMC: 4285787. DOI: 10.1002/oby.20663. View

19.

. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1):19-25. DOI: 10.1016/j.fertnstert.2003.10.004. View

20.

Bennett W, Aschmann H, Puhan M, Robbins C, Bayliss E, Wilson R . A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type II diabetes mellitus in people with multiple chronic conditions. J Clin Epidemiol. 2019; 113:92-100. DOI: 10.1016/j.jclinepi.2019.03.014. View